Intelligent Bio Solutions Inc. announced its financial results for the fiscal fourth quarter and full year ending June 30, 2025.
The company showcased sequential and year-on-year revenue growth of 16% driven by increased demand for drug testing cartridges.
Fiscal 2025 marked a year of growth, supported by higher-margin cartridge sales, operational streamlining, and regulatory advancements.
Progress Toward FDA Clearance
INBS is actively pursuing FDA 510(k) clearance for its opiate test system for codeine in the U.S. to expand beyond Forensic Use Only settings.
Expansion Across Key Markets
Revenue growth in fiscal Q4 was driven by increased demand for drug testing cartridges and new distributor partnerships.
Operational Efficiencies
The company's focus on improving gross margins and operational discipline has strengthened its fundamentals.
- INBS achieved steady sequential revenue growth in the fiscal fourth quarter, reaching $843,884.
- The revenue increase was primarily fueled by higher sales of drug testing cartridges, contributing to the company's recurring revenue model.
As Intelligent Bio Solutions continues to advance on its FDA regulatory pathway and expand into new markets, the company's growth trajectory looks promising for the future.